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Abstract
Stimulation of tyrosine kinase receptors initiates a signaling cascade that activates PI3K. Activated PI3K uses PIP2 to generate
PIP3, which recruit Akt to the plasma membrane through its pleckstrin homology (PH) domain, permitting its activation by
PDKs. Activated Akt controls important biological functions, including cell metabolism, proliferation and survival. The PI3K
pathway is therefore an attractive target for drug discovery. However, current assays for measurement of PIP3 production
are technically demanding and not amenable to high-throughput screening. We have established a MCF-7-derived breast
cancer cell line, that stably co-expresses the PH domain of Akt fused to Renilla luciferase and YFP fused to a membrane
localization signal. This BRET biosensor pair permits to monitor, in real time, in living cells, PIP3 production at the plasma
membrane upon stimulation by different ligands, including insulin, the insulin analogue glargine, IGF1, IGF2 and EGF.
Moreover, several known inhibitors that target different steps of the PI3K/Akt pathway caused inhibition of ligand-induced
BRET. Cetuximab, a humanized anti-EGF receptor monoclonal antibody used for the treatment of cancer, completely
inhibited EGF-induced BRET, and the tyrosine kinase inhibitor tyrphostine AG1024 inhibited insulin effect on PIP3
production. Moreover, the effects of insulin and IGF1 were inhibited by molecules that inhibit PI3K catalytic activity or the
interaction between PIP3 and the PH domain of Akt. Finally, we showed that human serum induced a dose-dependent
increase in BRET signal, suggesting that this stable clone may be used as a prognostic tool to evaluate the PI3K stimulatory
activity present in serum of human patients. We have thus established a cell line, suitable for the screening and/or the study
of molecules with stimulatory or inhibitory activities on the PI3K/Akt pathway that will constitute a new tool for translational
research in diabetes and cancer.
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Introduction
The PI3K (phosphatidylinositol 3-kinase)/Akt pathway regu-
lates multiple biological processes such as metabolism, cell
proliferation, survival, migration and apoptosis [1,2]. It is therefore
no surprise that alterations in this pathway have been implicated in
the pathogenesis of many human diseases. The serine/threonine
kinase Akt/PKB (protein kinase B) belongs to the family of AGC
kinases (AMP/GMP kinase and protein kinase C) and consists of
three conserved domains, an amino-terminal PH (Pleckstrin
homology) domain, a central catalytic domain and a carboxy-
terminal regulatory domain. Activation of Akt is a multistep
process that is dependent on PI3K activity. The PI3K consists of a
p85 regulatory subunit and a p110 catalytic subunit. Upon growth
factor stimulation, tyrosine kinase receptors (RTKs) are activated
and autophosphorylate on tyrosine residues that serve as docking
sites for a number of Src homology 2 (SH2) domain-containing
proteins, such as the p85 regulatory subunit of PI3K. p85 can also
interact indirectly with RTKs through binding of its SH2 domains
to tyrosine phosphorylated residues on adaptor proteins, such as
IRSs (Insulin Receptor Substrates). The engagement of p85 to
activated receptors induces conformational changes that relieves
the intermolecular inhibition of the p110 catalytic subunit and
brings it near to its plasma membrane lipid substrate Phosphatidyl
Insositol Phosphate 2 (PIP2), which is phosphorylated to produce
PIP3 [3]. PIP3 then recruits PDKs (3-phosphoinositide-dependent
protein kinases) and Akt to the plasma membrane via their PH
domains, where they are subsequently phosphorylated and
activated [1,2]. PTEN (phosphatase and tensin homologue deleted
on chromosome 10) terminates the PI3K/Akt signaling by
dephosphorylating PIP3 into PIP2 [4].
The PI3K pathway controls a wide spectrum of important
functions, including metabolism, cell growth, proliferation, surviv-
al and motility, which, when deregulated, can drive tumor
progression. Therefore, this pathway constitutes an attractive
target for anti-cancer drug discovery [5]. However, measurement
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of PIP3 production in cells is technically demanding and not easily
amenable to high throughput screening assays. Although it has
been suggested that recruitment of Akt protein to the plasma
membrane could also occur through PIP3 independent mecha-
nisms [6], the PH domain of Akt (about 100 amino acids) is highly
specific for PIP3 and has been previously used, in fusion with a
green fluorescent protein, to visualize PIP3 production at the
plasma membrane using fluorescence microscopy [7,8]. Using this
specific domain, we recently developed a BRET-based assay that
permits to monitor, in real time, in living cells, ligand-induced
PIP3 production at the plasma membrane [9,10]. In this assay, the
yellow fluorescent protein (YFP) is fused with a membrane
targeting sequence (YFP-Mem), allowing its addressage at the
plasma membrane, and the PH domain of Akt is fused to Renilla
Luciferase (Luc-Akt-PH). Upon PIP3 production, the recruitment
of Luc-Akt-PH to the plasma membrane results in an energy
transfer between the luciferase and the YFP (BRET) that can be
monitored in living cells cultured in 96 well plates (Fig. 1A). This
assay constitutes an excellent tool for the search of molecules that
modulate the activity of the PI3K/Akt pathway. In this paper, we
took advantage of this simple and robust assay to generate a cell
line, derived from human breast cancer MCF (Michigan Cancer
Fondation)-7 cells, stably expressing the YFP-Mem and Luc-Akt-
PH BRET biosensor pair. We show that this cell line is indeed
capable of responding to different growth factors, and that the
effects of known inhibitors of the PI3K/Akt pathway can be
readily detected, indicating that this stable clone is suitable for
screening and/or studying inhibitors or activators of the PI3K/Akt
pathway.
Materials and Methods
Reagents
Most chemical reagents have been described previously [11,12].
LY294002 was purchased from Cell Signaling Technology, PIT-1
and DMPIT-1 from Cayman Chemical, and Tyrphostin AG1024
from Santa-Cruz. Growth factors and IGFBP1(Insulin-like growth
factor binding protein 1) were from PreproTech. Insulin and
Glargine were obtained from the hospital Cochin (AP-HP, Paris).
Cetuximab and Trastuzumab were obtained from the hospital
Saint-Louis (AP-HP, Paris). Human serum (AB) was from Pel-
Freez Biologicals. Centrifugal filter devices for size exclusion of
small molecules present in human serum were from Millipore
(Microcon 3 kDa).
Anti-Phopho-Akt S473 D9E was from Cell Signaling Technol-
ogy and anti-Akt H136 from Santa Cruz Biotechnology.
Expression Vectors
The vector coding for Luc-Akt-PH [9] was obtained using
Gateway Technology. Briefly, the Pleckstrin Homology (PH)
domain of mouse Akt1 was amplified by PCR and introduced into
the pDONR vector according to the manufacturer instruction.
The resulting vector was recombined with phRluc-Nter Gateway
destination vector (kindly provided by Dr. Patrick Le´cine, France)
according to the manufacturer instruction.
For selection using hygromycin B resistance, the cDNA coding
for YFP-targeted to the plasma membrane (pEYFP-Mem from
Clontech) was sub-cloned into pIREShyg3 (Clontech) by using the
following primers (59-CTAGCTAGCATGCTGTGCTGTAT-
GAGAAG-39 and 59-GTAGGATCCTT ACTTGTA-
CAGCTCGTCCAT G-39).
Generation of Stable Cell Lines
MCF-7 cells were first transfected with the vector Luc-Akt-PH
[9]. After cell dilution and geneticin selection (1 mg/ml), we
obtained Luc-Akt-PH stable clones. We then generated MCF-7
double stable clonal cells by transfecting one of the Luc-Akt-PH
stable clone with the vector pYFP-Mem containing the hygro-
mycin resistance gene. Transfected cells were subsequently diluted
to obtain isolated individual cells and then selected in the media
containing 1 mg/ml of geneticin plus 200 mg/ml hygromycin B.
Cell Culture
Parental MCF-7 cells, Luc-Akt-PH stable clonal cells and MCF-
7/B2 double stable clonal cells were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 4.5 g/l glucose and
10% FBS (fetal bovine serum) [13]. One mg/ml of geneticin were
added to the media for Luc-Akt-PH stable cells and 1 mg/ml of
geneticin plus 200 mg/ml of hygromycin B were added to the
media for double stable clonal cells.
Western-blotting
MCF-7/B2, MCF-7/Luc-Akt-PH and parental MCF-7 cells
were cultured in 6-well plates. After insulin stimulation, cells were
lysed in ice-cold buffer containing 50 mM Tris-HCl (pH 8),
137 mM NaCl, 10% (v/v) glycerol, 1% (v/v) NP40, 50 mM NaF,
10 mM di-sodium b-glycerophosphate, 1 mM Na3VO4, and
protease inhibitors (1 mg/ml pepstatin, antipain, leupeptin, apro-
tinin and AEBSF). Proteins were then analysed by SDS-PAGE
(Sodium dodecyl Sulfate-Poly Acrylamide Gel Electrophoresis)
followed by western-blotting [14]. Western blots were scanned on
the Odyssey Infrared Imaging System (LI-COR Biosciences).
BRET Assay
The BRET signal has been defined previously as the ratio
530 nm/485 nm obtained when YFP- and Luciferase-fused
partners are present, corrected by the ratio 530 nm/485 nm
obtained under the same experimental conditions, when only the
partner fused to luciferase is present in the assay [15]. For this
purpose, in the present study, the MCF-7/Luc-Akt-PH stable
clone was cultured in parallel and submitted to the same
treatments as the MCF-7/B2 clone. MCF-7/Luc-Akt-PH and
MCF-7/B2 stable cells were seeded in 96 wells. Cells were washed
with PBS and then incubated for 5 min in PBS in the presence of
2.5 mM coelenterazine. Ligands were then added, and light
emission acquisition at 485 nm and 530 nm was started immedi-
ately [16,17]. To study the effects of different inhibitors, cells were
first preincubated with inhibitors for 1 h (AG1024, LY294002,
Cetuximab, Trastuzimab) or for 4 h (PIT-1 or DMPIT-1). Cells
were then washed with PBS, incubated for 5 min in PBS
containing 2.5 mM of coelenterazine as well as the inhibitors,
and then ligands were added. BRET signal was expressed in
milliBRET units (mBU) [15].
Fluorescence Microscopy
MCF-7/B2 cells were seeded on Lab-TekTM chamber slide,
fixed with 4% paraformaldehyde and the nuclei were stained with
DAPI (49,6-diamidino-2-phenylindole). The subcellular expression
of YFP-Mem was visualized by Lecia DMI600 inverted micro-
scope. YFP fluorescence was observed using a FITC (Fluorescein
isothiocyanate) filter (excitation: 450–490 nm; emission: 500–550),
and the nuclei were visualized using a DAPI filter (excitation: 340–
380 nm; emission: 450–490 nm). Images were obtained by
deconvolution analysis.
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Figure 1. Development of a human breast cancer-derived clone stably expressing a BRET-based PIP3 biosensor. (A) Principle of the
BRET-based assay used to monitor PIP3 production in living cells. Activation of the PI-3 kinase by tyrosine kinase receptors induces phosphorylation of
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Proliferation Assay by YFP Fluorescence Measurement
All measurements of YFP fluorescence (excitation at 480 nm
and emission at 532 nm) were performed at room temperature
using Typhoon Laser scanner (GE Healthcare). MCF-7/Luc-Akt-
PH and MCF-7/B2 cells were seeded in 96-well microplates at a
density of 15000 cells per well. The first fluorescent measurement
was performed on the next day (Day 0) and culture media were
then replaced by fresh media containing only 0.1% FBS. Cells
were then cultured for 48 h in absence or presence of 1 mM
insulin and various inhibitors (high insulin concentrations were
used in proliferation assays, in order to compensate for insulin
degradation that may occur during long-term incubations (24 or
48 h) in medium containing low amount of serum). Fluorescent
measurements were carried out after 24 h (Day 1) and 48 h (Day
2). Each experimental condition was performed in triplicate.
Specific YFP fluorescence of MCF-7/B2 cells was obtained by
substracting the fluorescence obtained with the MCF-7/Luc-Akt-
PH cells cultured in parallel under the same experimental
conditions (background fluorescence). The effects of treatments
on cell proliferation were obtained by dividing the specific YFP
fluorescence measured on the day of the assay by the initial
fluorescence (specific YFP fluorescence measured at Day 0).
Statistical Analysis
Statistical analyses were performed by ANOVA (Analysis of
variance) followed by Tukey’s test using Prism Software (Graph-
Pad, San Diego, CA, USA).
Results
Generation of Stable Clonal Cell Lines
MCF-7 cells were transfected with Luc-Akt-PH cDNA, and
after geneticin selection, a clone stably expressing Luc-Akt-PH was
used for establishing the double transfected cell line. Double clonal
cell lines (MCF-7 cells stably expressing Luc-AKT-PH and YFP-
Mem) were obtained from this stable clone by transfection with the
vector pEYFP-Mem bearing hygromycin B resistance. After
selection in the presence of both geneticin and hygromycin B,
four clones expressing both constructs were obtained. One clone
was not responsive to insulin (not shown), whereas in the three
other clones, increased BRET was observed upon insulin
stimulation, with clone B2 being the most responsive (Fig. 1B).
Fluorescent microscopy showed that YFP-Mem was indeed
correctly targeted at the plasma membrane in this clone
(Fig. 1C). To verify that expression of Luc-Akt-PH and YFP-
Mem did not alter the activity of the PI3K/Akt signaling pathway,
we compared Akt phosphorylation in Luc-Akt-PH and B2 clones
with the parental MCF-7 cell line upon insulin stimulation.
Western-blotting experiments with anti-phosphoAkt antibody
showed that similar levels of phosphorylation were obtained after
5, 10 and 15 min of stimulation with 100 nM insulin (Fig. 1D).
To ensure that the B2 clone can be stored frozen and submitted
to freeze/thaw cycles without losing its reporter properties, we
evaluated insulin responsiveness of the cells before and after
several weeks of storage in liquid nitrogen (Fig. 1E). We observed
that insulin dose-dependently stimulated BRET. A dose-response
curve (established using insulin-induced BRET values at the
plateau) indicated that insulin stimulated PIP3 production with a
half maximal effective concentration (EC50) of 20,1867.93 nM.
After several weeks in liquid nitrogen, the clone was thawed out,
amplified in 75 cm2 flasks and then plated in 96 well plates for
reassessment of insulin responsiveness. The new dose-response
curve was perfectly super-imposable to the one obtained prior to
the freeze/thaw cycle, and the EC50s of insulin remained identical
(EC50 of 20.1867.93 nM before and 18.7664.85 nM after
freezing/thawing, n = 6 to 11). This indicated that a freeze/thaw
cycle of B2 cells did not change their response to insulin. We thus
chose clone B2 for further characterization.
Ligand-induced PIP3 Production in MCF-7/B2 Clone
We then evaluated the effects of IGF1 (Insulin-like growth factor
1), IGF2 (Insulin-like growth factor 2), EGF (Epidermal Growth
Factor) and glargine (an insulin analogue used in the treatment of
diabetes) on PIP3 production in the MCF-7/B2 clone. We
observed that these ligands increased BRET signal in a dose-
dependent manner (Fig. 2A). Interestingly, whereas IGF1, IGF2
and glargine-induced signals reached a plateau and remained
stable during the course of the experiment, EGF produced a
transient increase in BRET signal, which returned to basal levels
within 20 min after stimulation. Dose-response curves were
established (Fig. 2B) using ligand-induced BRET (BRET above
basal at the plateau for IGF1, IGF2 and glargine, or at the peak
value for EGF). IGF1 (EC50 of 0.3460.05 nM, n= 6 to 8)
stimulated PIP3 production much more efficiently than insulin
(EC50 of 20.1867.93 nM, n= 11, p,0.001). IGF1 was also more
efficient than IGF2 (EC50 of 16.75610.01 nM, n=4, p,0.01).
The EC50 of EGF (4.0960.88 nM, n=3) was intermediary
between that of IGF-1 and IGF2. Glargine, in vitro, is known to
activate IGF1R (IGF1 receptor) and Insulin/IGF1 hybrid
receptors with higher efficiency than insulin [9,18]. We observed
that glargine (EC50 of 1.9860.87 nM) stimulated PIP3 production
much more efficiently than insulin in B2 cells (n = 4, p,0.01). In a
previous study, we measured EC50 for stimulation of PIP3
production by IGF1, insulin and glargine in the parental MCF-7
cells transiently expressing the Luc-Akt-PH/YFP-Mem biosensor
pair [9]. The EC50s obtained in the present study are in full
agreement with those obtained in our previous study, indicating
PIP2 into PIP3 and recruitment of Akt to the plasma membrane through its PH domain. To monitor PIP3 production, MCF-7 cells were stably
transfected with the PH domain of Akt fused to luciferase (Luc-Akt-PH) and YFP fused to a membrane localization sequence (YFP-membrane).
Recruitment of Luc-Akt-PH to the plasma membrane by PIP3 results in energy transfer between Luc-Akt-PH and YFP-membrane. This permits to study
the pharmacological properties of ligands that activate this pathway, and to evaluate the effects of inhibitory molecules acting on (I) the extracellular
part of receptors, (II) the tyrosine kinase activity of the receptors, (III) the catalytic activity of the PI3K, and (IV) the interaction between PIP3 and the PH
domain of Akt. (B) Transfection of a MCF-7 clone stably expressing Luc-Akt-PH with YFP-membrane cDNA gave rise to 4 sub-clones stably expressing
both constructs. Ligand-induced BRET could be detected in only 3 sub-clones (B2, D2, C2). Preliminary BRET experiments indicated that insulin-
induced BRET was higher with clone B2. (C) Surface expression of pEYFP-Mem in MCF-7/B2 cells was studied by fluorescence microscopy. YFP
fluorescence was detected using a FITC filter and nuclei were visualized using a DAPI filter. The image was obtained by deconvolution analysis. (D)
Western-blotting experiment showed that expression of Luc-Akt-PH alone or together with YFP-membrane does not affect insulin-induced
phosphorylation of endogenous Akt. (E) Insulin dose-dependently stimulated PIP3 production in MCF-7/B2 cells. Left panel: typical real-time
experiment showing basal and insulin-stimulated BRET. Right panel: insulin-induced BRET (BRET above basal at the plateau) was determined for each
insulin concentration to establish dose-response curves. Results are means6 S.E.M. (standard error of the mean) of 6 to 11 independent experiments.
The freeze-thaw cycle did not affect the sensitivity of the cells to insulin stimulation.
doi:10.1371/journal.pone.0092737.g001
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Figure 2. Effect of IGF1, IGF2, EGF and glargine on PIP3 production in MCF-7/B2 cells. (A) Typical experiments showing real-time effects of
IGF1, IGF2, EGF and glargine on PIP3 production in MCF-7/B2 cells. (B) Dose-dependent effect of IGF1, IGF2, EGF, glargine and insulin on PIP3
production in MCF-7/B2 cells. Ligand-induced BRET (BRET above basal) at the plateau (IGF1, IGF2, Insulin, Glargine) or at the peak (EGF) was
determined for each ligand concentration and was used to establish dose-response curves. Results are means 6 S.E.M. of 3 to 8 independent
experiments. EC50 for insulin, IGF1, IGF2, EGF and glargine are given in the result section.
doi:10.1371/journal.pone.0092737.g002
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that the pharmacological properties of the parental cell line are
preserved in MCF-7/B2 clone.
Effect of Inhibitors of the RTK/PI-3 Kinase Pathway on
BRET in MCF-7/B2 Cells
We then investigated whether the MCF-7/B2 clone could be
used to study the effects of inhibitors that target the PI3K pathway
at different levels (Fig. 1).
We firstly studied the effect of Cetuximab, a chimeric
humanized antibody that inhibits EGFR (EGF receptor) [19].
We observed that whereas Cetuximab had no effect on basal
BRET signal, it completely abrogated the effect of EGF on PIP3
production (Fig. 3A). The specificity of this inhibitory effect was
demonstrated by the absence of inhibition of IGF-1-induced
BRET by Cetuximab (Supplementary Fig. S1A). Moreover,
Trastuzumab, which specifically inhibits HER2 (Human epider-
mal growth factor receptor 2) [20], had no effect on basal or EGF-
induced BRET in these cells (Supplementary Fig. S1B), in
agreement with the HER2 negative phenotype of MCF-7 cells
[21].
The Tyrphostin AG1024 is a protein tyrosine kinase inhibitor
that selectively inhibits IR (insulin receptor) and IGF1R [22,23].
Whereas AG1024 had no significant effect on basal-BRET, it
completely inhibited insulin-induced BRET signal (Fig. 3B).
Therefore, inhibitors of RTK induce an inhibition of PIP3
production that can be detected using MCF-7/B2 cells.
We also evaluated the effect of LY294002, a known inhibitor of
the catalytic activity of PI3K [24], on basal, insulin, and IGF1-
stimulated BRET signal. We observed that LY294002 significantly
inhibited basal (p,0.01) and ligand-induced (p,0.05) PIP3
production (Fig. 3C and Supplementary Fig. S2A). Recent studies
indicated PI3K/Akt signaling pathway can be inhibited by small
non-phosphoinositide molecules that disrupt the interaction
between PIP3 and the PH-domain of Akt [25]. Binding of these
molecules to Akt-PH domain impairs Akt recruitment to the
plasma membrane and its activation by PDKs. We evaluated
whether the inhibitory effects of two non-phosphoinositide PIP3
inhibitors, PIT-1 and DMPIT-1, could be detected in the MCF-7/
B2 clone. PIT-1 had no effect on basal BRET signal and only
marginal effects on IGF1 (Fig. 3D) and insulin-stimulated
(Supplementary Fig. S2B) BRET signals. DMPIT-1 significantly
(p,0.05) inhibited IGF-1 (Fig. 3E) and insulin-stimulated (Sup-
plementary Fig. S2C) BRET signals. The higher inhibitory effect
of DMPIT-1 compared to PIT-1 on this signaling pathway has
been described previously and probably reflects its higher cell
permeability [25].
The Effect of Inhibitors on MCF-7/B2 Cell Proliferation can
be Directly Evaluated by Measuring YFP Fluorescence
Since MCF-7/B2 cells stably express YFP, we evaluated
whether the effects of inhibitors of the PI3K pathway on cell
proliferation could be monitored in parallel by a simple
measurement of the YFP fluorescence. We first evaluated the
effect of the tyrphostin AG1024 on cell proliferation. As shown in
Figure 4A, insulin induced an increase in cell proliferation,
resulting in a significant increase in fluorescence at Day 1 (p,0.05)
and a more marked increase at Day 2 (p,0.001). AG1024
treatment significantly reduced basal cell proliferation (p,0.05),
and completely abrogated (p,0.001) the stimulatory effect of
insulin on proliferation (Fig. 4A).
The PI3K inhibitor LY294002 also inhibited insulin-induced
cell proliferation (Fig. 4B), and this effect was more readily
observed at Day 2 (p,0.001).
Figure 3. Effect of inhibitors of the PI3K/Akt signaling pathway
on BRET signal in MCF-7/B2 cells. (A) MCF-7/B2 cells were
preincubated for 1 h in absence or presence of 20 ng/ml of the
humanized anti-EGFR antibody Cetuximab. Cells were then stimulated
with EGF (32 nM), and light emission acquisition started immediately. A
typical real-time BRET experiment (left panel) and the mean 6 SEM of
BRET values at the peak (right panel) are shown (n= 3). (B) MCF-7/B2
cells were preincubated for 1 h in absence or presence of 25 mM of the
tyrphostin AG1024. Cells were then stimulated with 100 nM insulin, and
light emission acquisition started immediately. A typical real-time BRET
experiment (left panel) and the mean 6 SEM of BRET values at the
plateau (right panel) are shown (n= 3). (C) MCF-7/B2 cells were
preincubated for 1 h in absence or presence of 25 mM of the PI3K
inhibitor LY294002. Cells were then stimulated with 10 nM IGF1 and
light emission acquisition started immediately. A typical real-time BRET
experiments (left panel) and the mean 6 SEM of BRET values at the
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We also evaluated the effect of PIT-1 and DMPIT-1, and found
that both compounds significantly inhibited (p,0.001) insulin-
induced cell proliferation (Fig. 4C).
These results support the idea that the biological activity of
molecules that modulate PIP3 signaling pathway can be evaluated
in parallel using a simple fluorescent measurement to monitor
their effects on cell proliferation.
The B2 Clone can be used to Evaluate the Biological
Activity of Human Serum
Human serum contains several molecules and growth factors
that can activate the PI3K pathway. We therefore tested whether
the MCF-7/B2 cell line could be used to monitor PI3K
stimulatory activity potentially present in human serum. MCF-
7/B2 cells were cultured overnight in medium containing only
0.1% FBS. Cells were then stimulated with PBS containing 1 to
10% of commercially available human serum. As shown in
Figure 5A and B, human serum can induce PIP3 production in a
dose-dependent manner. Heating the serum at 95uC for 1 h
completely abolished its ability to stimulate PIP3 production,
indicating that the active molecules are destroyed by the heat. In
order to determine whether the active factors present in serum
corresponded to small molecules such as metabolites, steroid
hormones or small peptides, we centrifuged human serum on a
centrifugal filter device with a molecular weight cut-off of 3 kDa,
and evaluated the PIP3 stimulatory activity present in the low- and
high-molecular weight fractions (filtrate and retentate fractions,
respectively). We observed that the low (,3 kDa) molecular
weight fraction had no effect on PIP3 production, whereas the
PIP3-stimulatory activity was present in the high (.3 kDa)
molecular weight fraction (Fig. 5C). Moreover, the stimulatory
activity in the retentate was significantly higher (p,0.01) than the
initial activity present in non-filtrated serum, suggesting that some
small molecules with inhibitory activity may have been lost during
filtration.
IGF1 and IGF2 are known to be strong stimulators of MCF-7
cell growth, and our results demonstrated that these growth factors
stimulated PIP3 production very efficiently in the MCF-7/B2 cell
line (Fig. 2). We therefore hypothesized that IGF1 and/or IGF2
could be the active factors present in human serum. IGFBP1
(Insulin-like growth factor binding protein-1) is a secreted protein
that binds to and inhibits the stimulatory activity of IGF1 and
IGF2 on IGF-1R [26,27]. To determine whether the PI3K
stimulatory activity present in serum was mediated by IGFs, the
serum was pre-incubated with recombinant IGFBP1 for 1 h prior
to stimulation of MCF-7/B2 cells. IGFBP1 alone had no effect on
PIP3 production in B2 cells, whereas it completely inhibited the
stimulatory effect of 5% serum (Fig. 5C). As shown in Supple-
mentary Figure S3, the inhibitory effect of IGFBP1 was dose-
dependent, with a maximal inhibitory activity at 50 mM IGFBP1.
Together, these results demonstrate that the MCF-7/B2 clone can
be used to evaluate PIP3 stimulatory activity present in human
serum, and that in the commercial batch of human serum used in
this study, this stimulatory effect is mediated by a heat-sensitive
molecule with a molecular weight higher than 3 kDa, the activity
of which is inhibited by the presence of IGFBP1, suggesting that
IGF1 and/or IGF2 could be the factors responsible for activation
of the PI3K pathway.
Discussion
Deregulation of the PI3K pathway has been implicated in many
human diseases. For instance, hyperactivation and deficiency of
this pathway are associated with the development of cancer and
diabetes, respectively. The PI3K pathway is thus a very attractive
target for drug screening. For the development of molecules that
modulate this pathway, it is important to have a simple, fast and
robust assay to measure PI3K activation. Typical methods to
measure PI3K activity involve extraction of radioactive products
after 32P labeling of phosphoinositide substrates and subsequent
separation using thin-layer chromatography or High-performance
liquid chromatography (HPLC) [28]. These highly time-consum-
ing and costly assays produce radioactive waste and are not
suitable for high-throughput screening of molecules. More
recently, PI3K activity assays based on ELISA have been
developed [29], eliminating the need of radioactivity and thin
layer chromatography or HPLC steps. However, these assays
remain time-consuming, as they involve extraction, incubation,
separation and washing steps. In contrast to these non-homoge-
nous and time-consuming methods, the stable cell line that we
described here provides a simple and robust alternative for the
study of molecules and ligands that modulate the PI3K pathway.
Indeed, we showed that the activation of the PI3K pathway by
insulin and growth factors can be monitored in real time, and
pharmacological profiles of activation by endogenously expressed
receptors could be established for each ligand in dose-response
experiments. Whereas both EGFR and IGF1R display high (sub-
namolar) affinity for their respective ligands, MCF-7 cells express
much lower levels EGFR than IGF1R (3000 EGFR/cell versus
20000 to 100000 IGF1R/cell) [30–34]. Although IR are also
highly expressed in MCF-7 cells (up to 100000 IR/cell [35]), a
large proportion of IR are engaged in IR/IGF1R hybrids [9,36],
which display much higher affinity for IGF1 than for insulin
[9,37–39]. Thus, the pharmacological profiles for PIP3 production
induced by the different ligands used in the present study are in
agreement with expression levels and pharmacological properties
of their cognate receptors. Indeed, a study of the effect of these
ligands on proliferation of MCF-7 cells showed similar order of
potency of the different ligands (IGF1.EGF.IGF2.Insulin)
[40]. Moreover, in a more recent study using non-transfected
MCF-7 cells [9], EC50s of insulin, IGF1 and Glargine for Akt
phosphorylation, measured by in-cell western, were found to be
very similar to EC50s of these ligands for PIP3 production in
MCF-7/B2 cells.
Interestingly, EGF-induced PIP3 production was transient,
reaching a peak between 5 and 10 min after stimulation. In
agreement with this observation, several studies have shown, in
different cell models, that upon EGF stimulation, activation of
EGFR and its downstream signaling pathways, including PI3K/
Akt pathway, are transient, due to rapid internalization and down-
regulation of the receptor as well as to negative feedback loops in
the signaling pathways [28,41–44]. Although performing time-
course and dose-response experiments using classical methods for
PIP3 production measurements is technically highly demanding,
one study, using rabbit corneal epithelial cells metabolically
labeled with 32P-phosphate, showed that EGF-stimulated PIP3
production was transient, peaking at about 5 min of stimulation,
with an EC50 in the nanomolar range [28]. Therefore, these
plateau (right panel) of 3 independent experiments are shown. (D, E)
MCF-7/B2 cells were preincubated for 4 h in absence or presence of
10 mM of the inhibitors of Akt-PH/PIP3 interaction PIT-1 (D) and DMPIT-1
(E). Cells were then stimulated with 10 nM IGF1, and light emission
acquisition started immediately. Typical real-time BRET experiments
(left panels) and the mean 6 SEM of BRET values at the plateau (right
panels) of 3 to 4 independent experiments are shown. Statistical
analysis was performed using ANOVA followed by Tukey’s test. *, P,
0.05; **, P,0.01; ***, P,0.001; NS, Non significant.
doi:10.1371/journal.pone.0092737.g003
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Figure 4. The effects of treatments on MCF-7/B2 cell proliferation can be monitored by YFP fluorescence measurement. MCF-7/B2
cells were plated in 96 well plates at a density of 15000 cells/well. 24 h after plating, YFP fluorescence in each well was measured at 530 nm after
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kinetics and pharmacological profile are very similar to those
obtained for EGF-induced PIP3 production measured by BRET in
MCF-7/B2 cells.
We also showed that our cell line permits the detection of the
inhibitory effects of molecules acting on the extra-cellular part of
receptors, on their tyrosine kinase activities, on the catalytic
activity of PI3K or on the interaction between PIP3 and the PH
domain of Akt. Therefore, the MCF-7/B2 clone can be used for
the identification and/or analyses of activators or inhibitors of the
PI3K pathway acting at different levels, from ligand binding to Akt
recruitment to the membrane. More specifically, we demonstrated
that the inhibitory effect of a humanized monoclonal antibody,
such as Cetuximab (which is used for the treatment of human
cancers [45]) can be studied using MCF-7/B2 cells. Allosteric
inhibitors of Akt that interfere with its binding to PIP3, are also
being developed for the treatment of PI3K dependent cancers
[46–48]. As exemplified by the study of the effects of PIT-1 and
DMPIT-1, the efficiency of such inhibitors can be evaluated using
MCF-7/B2 cells.
In addition, we showed that the stable expression of YFP in
these cells permits to monitor cell proliferation by a simple
fluorescent measurement after 24 or 48 h of treatment. Therefore,
the stimulatory or inhibitory effects of molecules on cell
proliferation can be evaluated in parallel in 96 well plates.
However, differences between BRET and proliferation may also
be observed. Thus, whereas PIT-1 displayed lower efficiency
compared to DMPIT-1 in BRET experiments, both compounds
showed similar inhibitory effect on cell proliferation. This suggests
that differences in cell permeability between PIT-1 and DMPIT-1
[25] may impact their efficiency for short-term treatments (4 h
incubations in BRET experiments) but not for long-term
treatments (24 h–48 h incubations in proliferation experiments).
Although we have not examined in the present work the
potential usefulness of this cell line for in vivo applications, the
stable expression of luciferase should also permit to follow, by
charged-coupled device camera imaging, the effects of in vitro
identified molecules on tumor growth in vivo, after implantation of
MCF-7/B2 cells in immunodeficient mice.
Finally, this tool should allow the study of PI3K-stimulatory
activity present in biological fluids. Indeed, we showed that MCF-
7/B2 clone could be used to evaluate the effect of human serum
on PIP3 production. Serum is likely to contain various molecules
capable of stimulating or inhibiting the PI3K pathway. We
observed that a commercially available batch of human serum
stimulated PIP3 production in a dose-dependent manner. Inter-
estingly, the stimulatory activity appeared to be heat-sensitive and
was due to molecules with molecular weight higher than 3 kDa, as
this activity was lost in the low molecular weight fraction obtained
after centrifugation on a 3 kDa-cut-off size exclusion filtration
membrane.
In human serum, the biological activities of hormones, growth
factors and cytokines can be regulated by circulating binding
proteins [49–53]. More specifically, IGFBPs have been shown to
regulate the biological activity of IGFs [54]. Interestingly, we
observed that the stimulatory effect of human serum could be
completely abrogated by pre-incubation of the serum with
recombinant human IGFBP1. This suggests that IGFs may be
the principal molecules present in the batch of serum used in this
study that activate PI3K signaling. Various studies have shown
that high circulating levels of IGFs are associated with an
increased risk of several cancers [50]. The bioavailability of IGFs
is modulated by the IGFBP family that contains six structurally
similar proteins with high affinity for IGFs. Functioning as IGFs
carriers within the circulation, IGFBPs regulate IGFs action by
inhibiting or facilitating the binding of IGFs to IGF1R. IGFBPs
can inhibit IGFs action by sequestering IGFs away from IGF1R.
However, the interaction between IGFBPs and matrix compo-
nents may concentrate IGFs near their receptor, thus enhancing
IGFs activity [54,55]. IGFBPs proteolysis by IGFBPs-specific
proteases represents an essential mechanism for IGF release
[50,54,55]. Therefore, the biological activity of IGFs depends not
only on their concentration in the serum, but also on the relative
amount of IGFBPs and IGFBP-specific proteases [56,57]. Since
the PI3K-stimulatory activity present in human serum can be
directly evaluated using MCF-7/B2 cells, it could be envisaged to
use this cell line as a prognostic tool to predict the proliferative
potential of sera from patients. Obviously, additional studies, using
sera from different origins and pathologies, will be needed to
establish the value of MCF-7/B2 cells as a prognostic tool to
evaluate the proliferative activity present in the serum of patients.
MCF-7/B2 cells could also be of interest for evaluating the
consequence of hormonal or pharmacological treatments on
modulation of PI3K-stimulatory activity in serum. For instance,
glargine, a long-lasting insulin analogue used for the treatment of
diabetes, displays higher mitogenic properties on culture cells
in vitro, when compared to insulin. However, when injected in vivo,
glargine is rapidly converted into metabolites [58,59,60] with
pharmacological properties similar to insulin [9,18]. In order to
determine the consequences of glargine treatment on the
proliferative activity present in human serum, attempts have been
made to compare the effects of sera from insulin and glargine-
treated diabetic patients on the proliferation of MCF-7 cells [61].
However, proliferation assays on cultured cells are time consuming
(72 hours of cell culture in the above mentioned study), and the
number of cases evaluated remained very small (31 patients in
total), considerably limiting the clinical significance of this study.
In contrast, with MCF-7/B2 cells, the read-out (PIP3 production)
can be obtained very rapidly (BRET plateau reached after 10–15
minutes of incubation with 5% serum). Therefore, our cell line
should constitute an excellent tool to evaluate in clinical assays the
PI3K stimulatory activity present in sera from large cohorts of
patients treated with different insulin analogues or other medica-
tions. Finally, MCF-7/B2 cells could also be a useful tool to study
PIP3-stimulatory activity present in conditioned media from
normal or cancer cells, in order to evaluate whether proteins or
small molecules secreted by these cells may affect the PI-3 kinase
pathway through autocrine or paracrine mechanisms [27].
In summary, we have developed a human breast cancer cell line
expressing a BRET-based biosensor to monitor the PI3K/Akt
pathway. This cell line constitutes a powerful tool for the study of
excitation at 480 nm (D0). Cells were then treated with ligands and/or inhibitors, and fluorescence measurements were performed 24 h (D1) and 48 h
(D2) later using a Typhoon Laser scanner. The effects of treatments on cell proliferation were estimated by dividing the fluorescence after treatment
by initial fluorescence. Background fluorescence of the cells was obtained by culturing in parallel MCF-7/Luc-Akt-PH cells under the same
experimental conditions. (A) Cells were cultured in presence of 1 mM of insulin in absence or presence of the 25 mM of AG1024 (B) Cells were cultured
in presence of 1 mM of insulin in absence or presence of 50 mM of the PI3K inhibitor LY294002 (C) Cells were cultured in presence of 1 mM of insulin in
absence or presence of 10 mM of the inhibitors of Akt-PH/PIP3 interaction PIT-1 and DMPIT-1. Mean 6 SEM of fluorescence ratios of 3 to 4
independent experiments are shown. Statistical analysis was performed using ANOVA followed by Tukey’s test. *, P,0.05; **, P,0.01; ***, P,0.001;
NS, Non significant.
doi:10.1371/journal.pone.0092737.g004
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Figure 5. The PI3K stimulatory activity present in human serum can be evaluated using the MCF-7/B2 cells. (A, B) MCF-7/B2 cells were
starved overnight in culture medium containing only 0.1% FBS. Cells were then stimulated with PBS containing 0%, 1%, 2%, 5% or 10% human serum
A New Tool to Study Modulators of the PI3K/Akt Pathway
PLOS ONE | www.plosone.org 10 March 2014 | Volume 9 | Issue 3 | e92737
activators and inhibitors acting at different levels on this signaling
pathway. MCF-7/B2 cells could also be used in high-throughput
screening assays for the identification of new molecules that
modulate the PI3K/Akt pathway. Indeed, after seeding in 96 wells
plates, cells are ready to use for BRET experiments on the
following day. Moreover, taking advantage of the stable expression
of YFP, these cells can also be used to monitor the effect of
different treatments on cell proliferation by simple fluorescent
measurements. Finally, MCF-7/B2 cells can also be used for
evaluating the PI3K activity present in human serum.
Supporting Information
Figure S1 Effects of anti-EGFR and anti-HER2 antibod-
ies on IGF1 and EGF-stimulated PIP3 production. (A)
MCF-7/B2 cells were preincubated for 1 h in absence or presence
of 20 ng/ml of the humanized anti-EGFR antibody Cetuximab.
Cells were then stimulated with IGF1 (10 nM), and light emission
acquisition started immediately. A typical real-time BRET
experiment (left panel) and the mean 6 SEM of BRET values
at the plateau (right panel) are shown (n= 3). (B) MCF-7/B2 cells
were preincubated for 1 h in absence or presence of 20 ng/ml of
the humanized anti-HER2 antibody Trastuzumab. Cells were
then stimulated with EGF (32 nM), and light emission acquisition
started immediately. A typical real-time BRET experiment (left
panel) and the mean 6 SEM of BRET values at the peak (right
panel) are shown (n= 3). Statistical analysis was performed using
ANOVA followed by Tukey’s test. **, P,0.01; ***, P,0.001; NS,
Non significant.
(PDF)
Figure S2 Effect of inhibitors of PI3K signaling on
insulin-stimulated PIP3 production in MCF-7/B2 cells.
(A) MCF-7/B2 cells were preincubated for 1 h in absence or
presence of 25 mM of the PI3K inhibitor LY294002. Cells were
then stimulated with 10 nM insulin and light emission acquisition
started immediately. A typical real-time BRET experiment (left
panel) and the mean 6 SEM of BRET values at the plateau (right
panel) of 4 independent experiments are shown. (B, C) MCF-7/B2
cells were preincubated for 4 h in absence or presence of 10 mM of
the inhibitors of Akt-PH/PIP3 interaction PIT-1 (B) and DMPIT-
1 (C). Cells were then stimulated with 10 nM insulin, and light
emission acquisition started immediately. Typical real-time BRET
experiments (left panels) and mean 6 SEM of BRET values at the
plateau (right panels) of 3 to 5 independent experiments are
shown. Statistical analysis was performed using ANOVA followed
by Tukey’s test. *, P,0.05; **, P,0.01; ***, P,0.001; NS, Non
significant.
(PDF)
Figure S3 Dose-dependent effect of IGFBP1 on human
serum induced PIP3 production in MCF-7/B2 cells.
MCF-7/B2 cells were starved overnight in culture medium
containing only 0.1% FBS. Cells were then stimulated with 5%
human serum that had been pre-incubated for 1 h in presence of
increasing concentrations of IGFBP1. Means 6 SEM of BRET
values at the plateau of 4 to 7 independent experiments are shown.
Statistical analysis was performed using ANOVA followed by
Tukey’s test. *, P,0.05; **, P,0.01; ***, P,0.001.
(PDF)
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